Tag: Prescription Drugs
Upadacitinib Improves Ulcerative Colitis Outcomes at 12 Months
Risk for composite outcome was lower, including lower risks for intravenous steroid use and colectomy, within 12 months in sensitivity analysis
Tecovirimat No Aid for Time to Lesion Resolution With Mpox
Additionally, interim analysis shows that the antiviral is safe but has no effect on pain among adults with mild-to-moderate clade II mpox
DOJ Alleges CVS Facilitated Unlawful Sales, Violating Federal Opioid Regulations
β-Blocker Use Delays Motor Onset With Huntington Disease
β-blocker use also tied to reduced rate of worsening of symptoms in early motor-manifest disease
Empagliflozin Not Tied to Risk for New Nonproliferative Diabetic Retinopathy
Empagliflozin may lower risk for diabetic retinopathy progression
Poststroke Epilepsy Risk Varies With Antihypertensive Treatment
Risk for PSE was lower for patients treated with ARBs and higher for those receiving calcium channel blockers, beta-blockers
Technosphere Insulin + Insulin Degludec Noninferior to Usual Care in T1DM
Regimen of inhaled Technosphere insulin plus insulin degludec noninferior for mean hemoglobin A1c
Combo Treatment With Xalnesiran Shows Promise in Patients With Hep B
Highest percentage of patients with HBsAg loss after end of treatment for those receiving xalnesiran + immunomodulator
SABCS: Adding Camrelizumab to Neoadjuvant Chemo Beneficial in TNBC
Addition of camrelizumab improves pathological complete response in early or locally advanced triple negative breast cancer
SABCS: Imlunestrant Tied to Improved PFS for ER-Positive, HER2-Negative Breast Cancer With ESR1 Mutations
Imlunestrant leads to significantly longer progression-free survival among those with ESR1 mutations, but not in overall population
